On February 14, 2025, Urogen Pharma Ltd entered into an Asset Purchase Agreement to acquire assets from IconOVir Bio, Inc. for $4 million in shares and potential future payments totaling $15 million plus royalties based on sales of the acquired product ICVB-1042.